Repositioning Candidate Details

Candidate ID: R0844
Source ID: DB05667
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Levoketoconazole
Synonyms: Levoketoconazole
Molecular Formula: C26H28Cl2N4O4
SMILES: CC(=O)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Structure:
DrugBank Description: Levoketoconazole is a cortisol synthesis inhibitor that is being developed as a therapy for glucose and cholesterol control in patients with type 2 diabetes mellitus.
CAS Number: 142128-57-2
Molecular Weight: 531.431
DrugBank Indication: Investigated for use/treatment in diabetes mellitus type 2.
DrugBank Pharmacology: --
DrugBank MoA: Preliminary data suggests that DIO-902 increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-β-hydroxylase enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-α-demethylase, a key enzyme in cholesterol synthesis. In combination with a typical glucose-lowering agent, such as metformin, DIO-902 may enhance glucose control and improve total and LDL-cholesterol.
Targets: Cytochrome P450 11B1, mitochondrial; Lanosterol 14-alpha demethylase
Inclusion Criteria: Indication associated